merged_parkinsons-disease-exenatide-byetta.txt
<question_number>1</question_number>
<answer>Byetta</answer>

<question_number>2</question_number>
<answer>Aluminum</answer>

<question_number>3</question_number>
<answer>Parkinson's disease</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>12 months</answer>
<other>The article states "a larger but still preliminary study, published last year in the New England Journal of Medicine, found that a GLP-1 that is no longer on the market -- lixisenatide -- appeared to slightly slow progress of the disease over a year." A year equals 12 months.</other>

<question_number>6</question_number>
<answer>GLP-1 receptor agonists</answer>

<question_number>7</question_number>
<answer>Exenatide</answer>

<question_number>8</question_number>
<answer>Exenatide</answer>

<question_number>9</question_number>
<answer>Exenatide</answer>

<question_number>10</question_number>
<answer>Exenatide</answer>

<question_number>11</question_number>
<answer>Exenatide</answer>

<question_number>12</question_number>
<answer>Exenatide</answer>

<question_number>13</question_number>
<answer>Exenatide</answer>

<question_number>14</question_number>
<answer>Exenatide</answer>

<question_number>15</question_number>
<answer>Exenatide</answer>
<other>The article mentions exenatide is sold under the brand name Byetta.</other>

<question_number>16</question_number>
<answer>Exenatide</answer>